Advertisement

Quality of Life Research

, Volume 26, Issue 11, pp 3069–3073 | Cite as

Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD)

  • Kazuo YamadaEmail author
  • Eiichiro Kamagata
Brief Communication

Abstract

Purpose

Premenstrual dysphoric disorder (PMDD) refers to the depression that occurs during the premenstrual phase and remits soon after the onset of menses. It affects the quality of life (QOL) of patients with PMDD. Therefore, this preliminary survey from chart recordings aimed to understand the symptom appearance and QOL reduction patterns in patients with PMDD, and to examine the extent of the loss of their quality-adjusted life years (QALYs).

Methods

Participants were 66 untreated female patients with PMDD. Data on symptom appearance and QOL reduction during the menstrual cycle, and the EuroQoL-5D (EQ-5D) scores during the premenstrual phase and immediately after the completion of a menstrual period were collected.

Results

The mean EQ-5D score of the 66 patients with PMDD was 0.795 ± 0.120 (range 0.362–0.949), indicating that their expected mean loss of QALYs was about 0.14 years.

Conclusions

If untreated, PMDD is expected to cause a mean loss of QALYs of about 0.14 years. However, on accounting for the period from disease development to menopause, and subtracting the menstruation-free periods such as pregnancy and breastfeeding, patients with untreated PMDD are expected to experience a QALY loss of about 3 years during their lifetime.

Keywords

Quality-adjusted life years Premenstrual dysphoric disorder Quality of life EuroQoL-5D 

Abbreviations

CES-D

The Center for Epidemiologic Studies Depression scale

DSM

Diagnostic and Statistical Manual of Mental Disorders

EQ-5D

EuroQoL-5D

EQ-VAS

EuroQoL-visual analogue scale

HRQoL

Health-related quality of life

PMDD

Premenstrual dysphoric disorder

PMS

Premenstrual syndrome

QALY

Quality-adjusted life year

QOL

Quality of life

SSRI

Selective serotonin reuptake inhibitor

Notes

Acknowledgements

This work was supported by JSPS KAKENHI Grant Number JP26670544.

Compliance with ethical standards

Conflict of interest

The authors declares that they have no conflict of interest.

References

  1. 1.
    American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington: American Psychiatric Press.CrossRefGoogle Scholar
  2. 2.
    Johnson, S. R. (2004). Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: A clinical primer for practitioners. Obstetrics and Gynecology, 104(4), 845–859.CrossRefPubMedGoogle Scholar
  3. 3.
    Rapkin, A. J., & Winer, S. A. (2009). Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. Expert Review of Pharmacoeconomics & Outcomes Research, 9(2), 157–170.CrossRefGoogle Scholar
  4. 4.
    Hall, E., & Steiner, M. (2015). Psychiatric symptoms and disorders associated with reproductive cyclicity in women: Advances in screening tools. Women’s health, 11(3), 397–415.PubMedGoogle Scholar
  5. 5.
    Tajima, R., Kondo, M., Kai, H., Saito, C., Okada, M., Takahashi, H., et al. (2010). Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clinical and Experimental Nephrology, 14(4), 340–348.CrossRefPubMedGoogle Scholar
  6. 6.
    Saleem, F., Hassali, M. A., & Shafie, A. A. (2014). A cross-sectional assessment of health-related quality of life (HRQoL) among hypertensive patients in Pakistan. Health Expectations, 17(3), 388–395.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang, F., Griva, K., Lau, T., Vathsala, A., Lee, E., Ng, H. J., et al. (2015). Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. Quality of Life Research, 24(9), 2163–2171.CrossRefPubMedGoogle Scholar
  8. 8.
    Subramaniam, M., Abdin, E., Vaingankar, J. A., Nan, L., Heng, D., McCrone, P., et al. (2013). Impact of psychiatric disorders and chronic physical conditions on health-related quality of life: Singapore Mental Health Study. Journal of Affective Disorders, 147(1–3), 325–330.CrossRefPubMedGoogle Scholar
  9. 9.
    Saarni, S. I., Suvisaari, J., Sintonen, H., Pirkola, S., Koskinen, S., Aromaa, A., et al. (2007). Impact of psychiatric disorders on health-related quality of life: General population survey. British Journal of Psychiatry, 190, 326–332.CrossRefPubMedGoogle Scholar
  10. 10.
    Penner-Goeke, K., Henriksen, C. A., Chateau, D., Latimer, E., Sareen, J., & Katz, L. Y. (2015). Reductions in quality of life associated with common mental disorders: Results from a nationally representative sample. Journal of Clinical Psychiatry, 76(11), 1506–1512.CrossRefPubMedGoogle Scholar
  11. 11.
    American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, fourth edition, text revision; DSM-IV-TR. Washington: American Psychiatric Press.CrossRefGoogle Scholar
  12. 12.
    EuroQoL Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRefGoogle Scholar
  13. 13.
    Tsuchiya, A., Ikeda, S., Ikegami, N., Nishimura, S., Sakai, I., Fukuda, T., et al. (2002). Estimating an EQ-5D population value set: the case of Japan. Health Economics, 11(4), 341–353.CrossRefPubMedGoogle Scholar
  14. 14.
    Shiroiwa, T., Fukuda, T., Ikeda, S., Igarashi, A., Noto, S., Saito, S., et al. (2016). Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Quality of Life Research, 25(3), 707–719.CrossRefPubMedGoogle Scholar
  15. 15.
    Shah, N. R., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstetrics and Gynecology, 111(5), 1175–1182.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Steiner, M., Pearlstein, T., Cohen, L. S., Endicott, J., Kornstein, S. G., Roberts, C., et al. (2006). Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. Journal of Women’s Health, 15(1), 57–69.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of PsychiatryTohoku Medical and Pharmaceutical University HospitalSendaiJapan
  2. 2.Keio University Law SchoolTokyoJapan

Personalised recommendations